HomeHealth

Health

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

December 2, 2022

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies(TM) (HSB-1940) against PD-1, by combining Quatramers(TM) with OmniAb’s Picobodies(TM), via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies(TM) (HSB-1940) against PD-1, by combining Quatramers(TM) with OmniAb’s Picobodies(TM), via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets

December 2, 2022

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

December 2, 2022

Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

December 2, 2022

Veeva Announces Fiscal 2023 Third Quarter Results

Veeva Announces Fiscal 2023 Third Quarter Results

December 2, 2022

AbbVie Announces Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

AbbVie Announces Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

December 1, 2022

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

December 1, 2022

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

December 1, 2022

Compugen’s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

Compugen’s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

December 1, 2022

Dr. Anna Loengard Joins Clover Health Board of Directors

Dr. Anna Loengard Joins Clover Health Board of Directors

December 1, 2022

« 1 … 81 82 83 84 85 … 127 »